DXC011

DXC011 is a preclinical-stage antibody-drug conjugate (ADC) developed by Hangzhou DAC Biotechnology, specifically designed to target folate receptor alpha (FRα). It distinguishes itself from traditional ADCs by utilizing a dual-payload strategy, which involves the conjugation of two different cytotoxic agents to a single antibody. This approach is intended to enhance antitumor efficacy, broaden the therapeutic window, and potentially overcome resistance mechanisms that often limit the effectiveness of single-payload conjugates like mirvetuximab soravtansine. FRα is a well-validated target that is highly expressed in various solid tumors, including ovarian, lung, and breast cancers, while maintaining limited expression in normal tissues. Preclinical data presented at AACR 2026 suggests that DXC011 demonstrates potent antitumor activity and a favorable safety profile, supporting its development for the treatment of FRα-positive solid tumors.